Evidence map›Paper›PMID 25703249›Full record

ArticleBioorganic & medicinal chemistry2015

Novel 4-substituted-N,N-dimethyltetrahydronaphthalen-2-amines: synthesis, affinity, and in silico docking studies at serotonin 5-HT2-type and histamine H1 G protein-coupled receptors.

Rajeev Sakhuja, Krishnakanth Kondabolu, Tania Córdova-Sintjago, Sean Travers, Adam S Vincek, Myong Sang Kim, Khalil A Abboud, Lijuan Fang, Zhuming Sun, Clinton E Canal and 1 more

Open access · greenAbstract read
In one paragraph

Article in Bioorganic & medicinal chemistry, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Effects of (-)-MBP, a novel 5-HTPharmacology research & perspectives · 2023
    Article
  2. Ligand-directed serotonin 5-HTEuropean journal of pharmacology · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Rajeev SakhujaDepartment of Medicinal Chemistry and Department of Chemistry, University of Florida, Gainesville, FL 32610-0485, United States.
Krishnakanth KondaboluDepartment of Medicinal Chemistry and Department of Chemistry, University of Florida, Gainesville, FL 32610-0485, United States.
Tania Córdova-SintjagoDepartment of Medicinal Chemistry and Department of Chemistry, University of Florida, Gainesville, FL 32610-0485, United States; Center for Drug Discovery, Department of Pharmaceutical Sciences and Department of Chemistry and Chemical Biology, Northeastern University, Boston, MA 02115-5000, United States.
Sean TraversDepartment of Medicinal Chemistry and Department of Chemistry, University of Florida, Gainesville, FL 32610-0485, United States.
Adam S VincekDepartment of Medicinal Chemistry and Department of Chemistry, University of Florida, Gainesville, FL 32610-0485, United States.
Myong Sang KimDepartment of Medicinal Chemistry and Department of Chemistry, University of Florida, Gainesville, FL 32610-0485, United States.
Khalil A AbboudDepartment of Medicinal Chemistry and Department of Chemistry, University of Florida, Gainesville, FL 32610-0485, United States.
Lijuan FangDepartment of Medicinal Chemistry and Department of Chemistry, University of Florida, Gainesville, FL 32610-0485, United States.
Zhuming SunDepartment of Medicinal Chemistry and Department of Chemistry, University of Florida, Gainesville, FL 32610-0485, United States.
Clinton E CanalDepartment of Medicinal Chemistry and Department of Chemistry, University of Florida, Gainesville, FL 32610-0485, United States; Center for Drug Discovery, Department of Pharmaceutical Sciences and Department of Chemistry and Chemical Biology, Northeastern University, Boston, MA 02115-5000, United States.
Raymond G BoothDepartment of Medicinal Chemistry and Department of Chemistry, University of Florida, Gainesville, FL 32610-0485, United States; Center for Drug Discovery, Department of Pharmaceutical Sciences and Department of Chemistry and Chemical Biology, Northeastern University, Boston, MA 02115-5000, United States. Electronic address: ra.booth@neu.edu.
University of Florida · US

Funding

Serotonin 5HT2C Agonist Drugs with 5HT2A/2B Antagonist ActivityR01MH081193 · NIMH · UNIVERSITY OF FLORIDA · PI BOOTH, RAYMOND G. · 2008 to 2012
$1.8M
Novel Functionally-Selective Serotonin 5HT2 Drugs for Amphetamines Abuse/DisorderR01DA030989 · NIDA · UNIVERSITY OF FLORIDA · PI BOOTH, RAYMOND G., MORGAN, DRAKE · 2010 to 2014
$1.6M
Novel 5HT2C Agonist Drugs with 5HT2A Antagonist Activity for Cocaine AddictionR01DA023928 · NIDA · UNIVERSITY OF FLORIDA · PI BOOTH, RAYMOND G. · 2007 to 2010
$1.5M
NIDA NIH HHS DA030989NIDA NIH HHS R01 DA023928NIDA NIH HHS R01 DA030989NIMH NIH HHS MH081193NIMH NIH HHS R01 MH081193
6 · The paper itself

Abstract

Syntheses were undertaken of derivatives of (2S,4R)-(-)-trans-4-phenyl-N,N-dimethyl-1,2,3,4-tetrahydronaphthalen-2-amine (4-phenyl-2-dimethylaminotetralin, PAT), a stereospecific agonist at the serotonin 5-HT2C G protein-coupled receptor (GPCR), with inverse agonist activity at 5-HT2A and 5-HT2B GPCRs. Molecular changes were made at the PAT C(4)-position, while preserving N,N-dimethyl substitution at the 2-position as well as trans-stereochemistry, structural features previously shown to be optimal for 5-HT2 binding. Affinities of analogs were determined at recombinant human 5-HT2 GPCRs in comparison to the phylogenetically closely-related histamine H1 GPCR, and in silico ligand docking studies were conducted at receptor molecular models to help interpret pharmacological results and guide future ligand design. In most cases, C(4)-substituted PAT analogs exhibited the same stereoselectivity ([-]-trans>[+]-trans) as the parent PAT across 5-HT2 and H1 GPCRs, albeit, with variable receptor selectivity. 4-(4'-substituted)-PAT analogs, however, demonstrated reversed stereoselectivity ([2S,4R]-[+]-trans>[2S,4R]-[-]-trans), with absolute configuration confirmed by single X-ray crystallographic data for the 4-(4'-Cl)-PAT analog. Pharmacological affinity results and computational results herein support further PAT drug development studies and provide a basis for predicting and interpreting translational results, including, for (+)-trans-4-(4'-Cl)-PAT and (-)-trans-4-(3'-Br)-PAT that were previously shown to be more potent and efficacious than their corresponding enantiomers in rodent models of psychoses, psychostimulant-induced behaviors, and compulsive feeding ('binge-eating').

Indexed as

Computer SimulationBinding, CompetitiveBinding SitesCrystallography, X-RayHumansNaphthalenesProtein Structure, SecondaryReceptors, G-Protein-CoupledReceptors, Histamine H1Receptors, Serotonin, 5-HT2NaphthalenesReceptors, G-Protein-CoupledReceptors, Histamine H1Receptors, Serotonin, 5-HT25-HT(2)AminotetralinHistamine H(1)Molecular modelingSerotonin receptorsX-ray crystal structure

Identifiers

PMID25703249
PMCPMC4363177
OpenAlexW2094187744

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.